Resources
15 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 6/3/2022 (updated 3/27/2024)
During this session, Dr. Lopata discussed federal/HRSA investments focused on improving the health outcomes for and reducing health disparities among maternal and child health populations. More specifically, Dr. Lopata discussed the multiple programs/interventions funded by HRSA that together work (along with federal, state, regional, and local partners) to improve the prevention, screening, and treatment of opioid use disorder during pregnancy and Neonatal Abstinence Syndrome in the United States.
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 5/22/2020 (updated 3/28/2024)
To identify Finnegan Neonatal Abstinence Scoring Tool tems independently associated with the decision to use pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the treatment decision.
Posted 5/27/2020 (updated 3/28/2024)
Please see attached technical modules to help guide you as you work to address the opioid epidemic in your communities. They are a resource for you to identify best practices and implementation models for prevention, treatment, and recovery.
Posted 6/12/2020 (updated 3/28/2024)
Mother & Baby Substance Exposure Toolkit Best Practices All Best Practices came as a part of the California Medication Assisted Treatment Expansion Project
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 6/30/2021 (updated 4/2/2024)
This guidance publication is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families. National data show that from 2000 to 2009 the use of opioids during pregnancy increased from 1.19 to 5.63 per 1,000 hospital births (Patrick, Schumacher, Benneyworth, Krans, McAllister, & Davis, 2012). Because of the high rate of opioid use and misuse among all women, including pregnant women, medical, social service, and judicial agencies are having to confront this concern more often and, in some communities, at alarming rates.
This guidance document provides background information on the treatment of pregnant women with opioid use disorders, summarizes key aspects of guidelines that have been adopted by professional organizations across many of the disciplines, presents a comprehensive framework to organize these efforts in communities, and provides a collaborative practice guide for community planning to improve outcomes for these families. A set of appendices provides details on implementing the recommendations in the guide as well as a summary of lessons from one community’s experience over the past decade.
Posted 9/1/2021 (updated 4/2/2024)
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.